Pregnancy Warnings

Tretinoin topical Pregnancy and Breast Feeding Warnings

Tretinoin topical is also known as: Altinac, Atralin, Avita, Renova, Retin A Micro Gel, Retin A Micro Gel Pump, Retin-A, Retin-A and Renova, Retisol-A, Stie Vaa, Stie Vaa Forte, Stievaa, Tretin-X, Vitinoin

Overview

If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Tretinoin Gel while you are pregnant. If you are or will be breast-feeding while you use Tretinoin Gel, check with your doctor. Discuss any possible risks to your baby.

Tretinoin topical Pregnancy Warnings

Topical tretinoin has been assigned to pregnancy category C by the FDA. Oral tretinoin has been shown to be teratogenic and fetotoxic in high dose studies conducted in rats. Topical tretinoin was associated with fetal malformations and teratogenicity in some animal studies. There are no controlled data in human pregnancy. However, there have been reports of possible teratogenicity related to topical tretinoin use during early pregnancy, including case reports of holoprosencephaly, ear malformation, limb reduction defects. Some experts suggest that topical tretinoin does not increase the risk of malformations, while others recommend avoiding its use during the first trimester or during the entire pregnancy. Topical tretinoin is only recommended for use during pregnancy when benefit outweighs risk.

There have been two reports of possible teratogenicity associated with topical tretinoin. In both cases, the mother had used tretinoin before conception and for several weeks during the first trimester. One baby was born with an ear malformation and the other had multiple congenital defects (including limb and heart abnormalities). A retrospective study of 215 women presumably exposed to topical tretinoin during the first trimester was conducted by Jick and colleagues. The occurrence of major anomalies among offspring of exposed women was 1.9% as opposed to 2.6% for those born to 430 age-matched nonexposed women. The authors concluded that topical tretinoin was not associated with an increased risk for major congenital disorders.

Tretinoin topical Lactation Warnings

There are no data on the excretion of tretinoin topical into human milk. The manufacturer recommends that caution be used when administering tretinoin to nursing women.

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This drug information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information in contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.


MedNotes
Advertisement

(web2)